Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 7 records in total 7
    records per page




    Clinical course of COVID-19 MESHD patients needing supplemental oxygen outside the intensive care unit

    Authors: Ayham Daher; Paul Balfanz; Maria Aetou; Bojan Hartmann; Dirk Müller-Wieland; Tobias Müller; Nikolaus Marx; Michael Dreher; Christian G Cornelissen

    doi:10.21203/rs.3.rs-95432/v1 Date: 2020-10-20 Source: ResearchSquare

    Purpose: Patients suffering from CVOID-19 mostly experience a benign course of the disease. Approximately 14 % of SARS-CoV2 infected MESHD patients are admitted to a hospital. Cohorts exhibiting severe lung failure MESHD in the form of acute respiratory distress syndrome MESHD ( ARDS MESHD) have been well characterized. Patients without ARDS MESHD but in need of supplementary oxygen have received much less attention. This study describes the diagnosis, symptoms, treatment and outcomes of hospitalized patients with COVID-19 MESHD needing oxygen support during their stay on regular ward.Methods: All 133 patients admitted to the RWTH Aachen university hospital with the diagnosis of COVID-19 MESHD were included in an observational registry. Clinical data sets were extracted from the hospital information system. This analysis includes all 57 patients requiring supplemental oxygen not admitted to the ICU.Results: 57 patients needing supplemental oxygen and being treated outside the ICU were analyzed. Patients exhibited the typical set of symptoms for COVID-19 MESHD. Of note, hypoxic MESHD patients mostly did not suffer from clinically relevant dyspnea MESHD despite oxygen saturations below 92 %. Patients had fever MESHD for 7 [2-11] days and needed supplemental oxygen for 8 [5-13] days resulting in an overall hospitalization time of 12 [7-20] days. In addition, patients had persisting systemic inflammation MESHD with CRP HGNC levels remaining elevated until discharge or death MESHD.Conclusion: This description of COVID-19 MESHD patients requiring oxygen therapy should be taken into account when planning treatment capacity. Patients on oxygen need long-term inpatient care.

    Screening and Analysis of COVID-19 MESHD cases in non-epidemic areas: A Retrospective Study

    Authors: Yan Zhu; Yan Guo; Juan Ma; Mao-shi Li; Jia-fei Chen; Ming Liu; Ze-hui Yan; Guo-hong Deng; Qing Mao; Hui-min Liu

    doi:10.21203/rs.3.rs-32811/v1 Date: 2020-06-01 Source: ResearchSquare

    Objective: To compare the epidemiological and clinical characteristics of confirmed and suspected corona virus disease MESHD 2019 ( COVID-19 MESHD) cases via the process of “triage-screening-isolation-transfer” in the hospitals of non-epidemic areas.Methods: The general data, epidemiological history, clinical symptoms, laboratory examination, and chest computed tomography (CT) imaging characteristics of 38 patients with suspected COVID-19 MESHD, admitted between January 21 and March 5, 2020, were analyzed.Results: According to the results of the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) ribonucleic MESHD acid (RNA) testing, the patients were divided into study group (RNA positive) and control group (RNA negative). Ultimately, 8 cases were RNA-positive and diagnosed as CDVID-19, and 30 cases were negative. Approximately half of the patients in the study group returned to Chongqing from Wuhan; this number was significantly larger than that of the control group (P<0.05). The number of subjects in close contact with the confirmed cases with SARS-CoV-2 RNA-positive and the incidence of aggregation was significantly larger in the study group than in the control group (both P<0.05). The clinical symptom of the study group was mainly low fever MESHD (with or without cough MESHD). The patients with decreased white blood cells (WBC) in the study group were significantly more than those in the control group (P<0.05). Both group had reduced lymphocytes (Lym) but the number of patients with increased C-reactive protein HGNC ( CRP HGNC) in the study group was significantly more than that in the control group (P<0.05). There were different degrees of chest CT abnormalities MESHD in both study and control group (P > 0.05). Conclusion: The epidemiological investigations in screening for infectious diseases MESHD is crucial. The risk of infection was high from the primary epidemic area and/or in close contact with the confirmed case. The most common form of clustering occurrence was family aggregation. CDVID-19 was mainly characterized by fever MESHD and respiratory symptoms, although asymptomatic infection may also occur. Decreased WBC, decreased Lym, and increased CRP HGNC are common characteristics but can also be combined with other respiratory tract virus infections MESHD. COVID 19 screening by chest CT alone had certain limitations in non- epidemic areas.

    Clinical and biochemical indexes of 11 COVID-19 MESHD patients and the genome sequence analysis of the tested SARS-CoV-2

    Authors: Zhikang Yu; Heming Wu; Qingyan Huang; Xuemin Guo; Zhixiong Zhong

    doi:10.21203/rs.3.rs-32414/v2 Date: 2020-05-29 Source: ResearchSquare

    BackgroundAt present, SARS-CoV-2 epidemic MESHD in the world rapidly spread. It is a serious global public health emergency.MethodsHere we described the clinical characteristics of 11 SARS-CoV-2 infected MESHD patients hospitalized in the Meizhou People's Hospital. And viral genome sequences of SARS-CoV-2 from these patients were analyzed.ResultsOf the 11 patients, six cases developed fever MESHD, nine cases developed cough MESHD, and two cases developed headache MESHD and chills. Four patients (36.4%) had underlying diseases. Pneumonia is the most common complication. The laboratory test results showed that there was no adult patients with increased LYM/LYM%. Most patients had normal total protein (TP) and albumin ( ALB HGNC), but only two patients had decreased. Most patients had increased or normal levels of erythrocyte sedimentation rate (ESR), C reactive protein HGNC ( CRP HGNC), activated partial thromboplastin time (APTT), fibrinogen HGNC (FIB), creatine kinase isoenzymes (CK-MB), and lactate dehydrogenase (LDH). Neutrophil (NEU) (r=0.664, P=0.026), CK-MB (r=0.655, P=0.029), blood urea nitrogen (BUN) (r=0.682, P=0.021) and SARS-CoV-2 virus cycle threshold (Ct) value were significantly correlated. Multiple sequence alignment (MSA) shows that we identified two different SNPs at positions 8781 and 28144, and have a completely linked genetic form of 8781C-28144T and 8781T-28144C.ConclusionsThe reports of these 11 cases in our hospital will provide useful information for the diagnosis, treatment and drug development of SARS-CoV-2.

    Clinical research and factors associated with prolonged duration of viral shedding in patients with COVID-19 MESHD

    Authors: Di Tian; Lin Wang; Xiankun Wang; Ziruo Ge; Shuping Cui; Yanli Xu; Rui Song; Meihua Song; Bing Han; Wei Zhang; Dawei Tan; Xingang Li; Yang Zhou; Sujuan Zhang; Li Yang; Peipei Meng; Le Sun; Xingwang Li; Zhihai Chen

    doi:10.21203/rs.3.rs-29818/v1 Date: 2020-05-19 Source: ResearchSquare

    Background Towards the end of December 2019, the Wuhan health commission declared an outbreak of clusters of pneumonia MESHD in patients. Sequencing indicated that this disease ( COVID-19 MESHD) was caused by a novel coronavirus (SARS-CoV-2). The outbreak of COVID-19 MESHD is currently still underway.Methods We recruited 75 SARS-CoV-2 infected MESHD patients admitted to the Center of Infectious Disease division 2 of Beijing Ditan Hospital from Jan 20 to Mar 20, 2020. Epidemiological, demographic, clinical, radiological features, laboratory data were analyzed.Results Of the 75 patients, 42(56%) patients were male and 33(44%) patients were female. The mean age of all patients was 41.5 ± 19.4 years. Male patients were more likely to become severe. There were 9 family clusters accounted for 44 patients. Patients classified as being severe had a higher frequency of fever MESHD upon admission than patients classified as moderate cases. For moderate patients, the median duration of viral shedding was 25(9.5, 42) days (range 1–63 days) from the first positive nucleic acid test compared to 14(9, 21.25) days (range 2–62 days) for severe cases. The difference between the two groups was statistically significant (p = 0.041). Cox regression analyses indicated that disease status and CRP HGNC were the factors that affect the duration of viral shedding. Virus clearance was significantly faster in severe patients compared to moderate patients(p = 0.011), and patients with CRP HGNC range in 2–10 times higher than upper limit of normal value had longer duration of viral shedding(p = 0.012). CRP HGNC and CD4 + T lymphocyte was negative correlated, and the relationship between CRP HGNC and CD4 + T lymphocyte was statistically significant (P = 0.003), with a correlation coefficient of -0.564. During the second week following the onset of illness, severe cases had higher WBC, NEU and CRP HGNC, but lower LYM, MON and EOS as compared with moderate cases (all P < 0.05). Severe cases still had lower lymphocyte counts and higher CRP HGNC than moderate cases in the third week.Conclusions Viral clearance was significantly prolonged in moderate patients, and those CRP HGNC in 2–10 times higher than upper limit of normal value. Immune response may affect the duration of viral shedding. Severe cases had a persistence lower lymphocyte count and higher CRP HGNC than moderate cases.

    Low albumin levels are associated with poorer outcomes in a case series of COVID-19 MESHD patients in Spain: a retrospective cohort study

    Authors: Roberto de la Rica; Marcio Borges; Maria Aranda; Alberto del Castillo; Antonia Socias; Antoni Payeras; Gemma Rialp; Lorenzo Socias; Lluis Masmiquel; Marta Gonzalez-Freire

    doi:10.1101/2020.05.07.20094987 Date: 2020-05-11 Source: medRxiv

    OBJECTIVE To describe the clinical characteristics and epidemiological features of severe (non-ICU) and critically patients (ICU) with COVID-19 MESHD at triage, prior hospitalization, in one of the main hospitals in The Balearic Islands health care system. DESIGN Retrospective observational study SETTING Son Llatzer University Hospital in Palma de Mallorca MESHD (Spain) PARTICIPANTS Among a cohort of 52 hospitalized patients as of 31 March 2020, 48 with complete demographic information and severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) positive test, were analyzed. Data were collected between March 15th, 2020, and March 31th 2020, inclusive of these dates. MAIN OUTCOMES Clinical, vital signs and routine laboratory outcomes at the time of hospitalization, including symptoms reported prior to hospitalization. Demographics and baseline comorbidities were also collected. Mortality was reported at the end of the study. RESULTS 48 patients (27 non-ICU and 21 ICU) resident in Mallorca, Spain (mean age, 66 years, [range, 33-88 years]; 67% males) with positive SARS-CoV-2 infection MESHD were analyzed. There were no differences in age or sex among groups (p >.05). Initial symptoms included fever MESHD (100%), coughing (85%), dyspnea MESHD (76%), diarrhea MESHD (42%) and asthenia MESHD (21%). The majority of patients in this case series were hospitalized because of low SpO2 (SpO2 below 90%) and presentation of bilateral pneumonia MESHD (94%) at triage. ICU patients had a higher prevalence of dyspnea MESHD compared to non-ICU patients (95% vs 61%, p = .022). Acute respiratory syndrome MESHD ( ARDS MESHD) was presented in 100% of the ICU-patients. All the patients included in the study required oxygen therapy. ICU-patients had lymphopenia MESHD as well as hypoalbuminemia MESHD. Inflammatory markers such as lactate dehydrogenase (LDH), C-reactive protein HGNC ( CRP HGNC), and procalcitonin were significantly higher in ICU patients compared to non-ICU (p < .001).Lower albumin levels were associated with poor prognosis measured as longer hospital length (r= -0.472, p

    Identification of a super-spreading chain of transmission associated with COVID-19 MESHD

    Authors: Ke Hu; Yang Zhao; Mengmei Wang; Qiqi Zeng; Xiaorui Wang; Ming Wang; Zhishui Zheng; Xiaochen Li; Yunting Zhang; Tao Wang; Shaolin Zeng; Yan Jiang; Dan Liu; Wenzhen Yu; Fang Hu; Hongyu Qin; Jingcan Hao; Jian Yuan; Rui Shang; Meng Jiang; Xi Ding; Binghong Zhang; Bingyin Shi; Chengsheng Zhang

    doi:10.1101/2020.03.19.20026245 Date: 2020-03-23 Source: medRxiv

    BackgroundSuper-spreading events were associated with the outbreaks of SARS and MERS, but their association with the outbreak of COVID-19 MESHD remains unknown. Here, we report a super-spreading transmission chain of SARS-CoV-2 involving an index patient, seven cancer MESHD patients, 40 health care workers and four family members. MethodsWe conducted a retrospective study to identify the index patient and the exposed individuals linked to a chain of transmission associated with COVID-19 MESHD. We collected and analyzed the data on demographic features, exposure history, clinical presentation, laboratory investigation, radiological examination, and disease outcome of these patients. ResultsWe identified the index patient and another presumptive "super-spreader", who initiated and amplified a super-spreading transmission chain associated with COVID-19 MESHD, respectively. There were 31 female and 21 male patients in this cohort, and the median age was 37 years (range: 22-79 years). Each of them had an exposure history with the index patient or his close contacts. Approximately 87% (45/52) of the patients had fever MESHD or other symptoms, 96% (50/52) had abnormal chest CT-scan findings, 86% of the tested patients (39/45) were positive for SARS-CoV-2 in the nasopharyngeal or throat swab specimen, 85% of the tested patients (29/34) were positive for SARS-CoV-2-specific IgM and/or IgG, 15% of the RT-PCR positive patients were tested negative for the specific IgM and/or IgG at the convalescent phase, and 15% of the RT-PCR negative patients were tested positive for the specific IgM and/or IgG. The severe patients experienced a significant decrease in oximetry saturation, lymphocyte, and platelet counts, along with a significant increase in C-reactive protein, D-dimer, and lactate dehydrogenase HGNC. All six fatal cases had comorbidities and five of the seven cancer MESHD patients (71%) died within 2-20 days of the disease onset. ConclusionsThe super-spreading events were associated with the outbreak of COVID-19 MESHD in Wuhan and its impact on disease transmission warrants further investigation. Cancer MESHD patients appeared highly vulnerable to COVID-19 MESHD. The finding that a significant portion of SARS-CoV-2 infected MESHD patients were tested negative for the serum specific IgM and IgG at the convalescent phase should be addressed by additional studies.

    Clinical characteristics of 51 patients discharged from hospital with COVID-19 MESHD in Chongqing,China

    Authors: liu lei; Gao Jian-ya

    doi:10.1101/2020.02.20.20025536 Date: 2020-02-23 Source: medRxiv

    Abstract BackgroundSince December 2019, Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)-infected disease MESHD ( Coronavirus Disease 2019 MESHD COVID-19 MESHD) emerged in Wuhan , Chinaand rapidly spread throughout Chinaeven throughout the world. We try to describe the epidemiological and clinical characteristics of COVID-19 MESHD in non-Wuhan areaand explore its effective treatment. MethodsRetrospective, single-center case series of the 51 hospitalized patients with confirmed COVID-19 MESHD at Chongqing University Three Gorges Hospital in Chongqing, China, from January 20 to February 3, 2020The discharge time was from January 29 to February 11, 2020. The main results and indicators of epidemiology, demography, clinical manifestation, laboratory examination, imaging data and treatment data of 51 patients with covid-19 MESHD were collected and analyzed. The changes of blood routine and biochemical indexes at discharge and admission were compared. Compare the clinical characteristics of severe patients (including severe and critical patients) and non- severe patients (general patients). Results Of 51 hospitalized patients with COVID-19 MESHD, the median age was 45 years (interquartile range, 34-51; range, 16-68 years) and 32 (62.7%) were men.43(84.3%)patients had been to Wuhan or Other Hubei areas outside Wuhanand 4(7.7%) patients had a clear contact history of COVID-19 MESHD patients before the onset of the disease, and 4(7.7%) patients had no clear epidemiological history of COVID-19 MESHD.Common symptoms included fever MESHD (43 [84.3%]), cough (38 [74.5%]) and fatigue MESHD (22 [43.1%]). Lymphopenia MESHD was observed in 26 patients (51.0%), and elevated C-reactive protein HGNC level in 32 patients (62.7%). Ground-glass opacity was the typical radiological finding on chest computed tomography (41 [80.4%])Local consolidation of pneumonia MESHD in some patients(17 [33.3%]).Most of the patients were treated with traditional Chinese medicine decoction (28 [54.9%])all of them received aerosol inhalation of recombinant human interferon a-1b for injection and oral antiviral therapy with Lopinavir and Ritonavir tablets (51 [100%]); Most of the patients were given Bacillus licheniformis capsules regulated intestinal flora treatment (44 [86.3%]). 10 patients (19.6%) received short-term (3-5 days) glucocorticoid treatment. Compared with non-severe patients (n = 44), severe patients (n = 7) were older (median age, 52 years vs 44 years), had a higher proportion of diabetes mellitus (4 [57.1%] vs 0 [0.0%]), most of them needed antibiotic treatment (7 [100%] vs 4 [9.1%], most of them needed nutritional diet (6 [85.7%) vs 0 [0.0%], and were more likely to have dyspnea (6 [85.7%] vs 5 [11.4%])most of them needed noninvasive mechanical ventilation (6 [85.7%] vs 0 [0.0%]). Except one patient died, the remaining 50 patients were discharged according to the discharge standard, the common clinical symptoms disappeared basically, the lymphocyte increased significantly (P=0.008), CRP HGNC decreased significantly (P <0.001). The median length of stay was 12 days (IQR, 9-13). ConclusionIn 51 single center cases confirmed as COVID-19 MESHD and discharged from the hospital, 13.7% of the patients were severe. The main clinical symptoms of patients with COVID-19 MESHD were fever, cough and astheniaSome patients had obvious dyspnea. They had clinical laboratory and radiologic characteristics. There is no specific drug treatment for the disease. For the treatment of COVID-19 MESHD, in addition to oxygen inhalation and antiviral treatment, attention should be paid to the dialectical treatment of traditional Chinese medicine, regulation of intestinal flora, nutritional support treatment and other comprehensive treatment.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.